LLY

1,061.41

+3.42%↑

JNJ

234.23

+2.48%↑

ABBV

217.56

+2.78%↑

UNH

384.16

+0.13%↑

AZN

188.09

+1.01%↑

LLY

1,061.41

+3.42%↑

JNJ

234.23

+2.48%↑

ABBV

217.56

+2.78%↑

UNH

384.16

+0.13%↑

AZN

188.09

+1.01%↑

LLY

1,061.41

+3.42%↑

JNJ

234.23

+2.48%↑

ABBV

217.56

+2.78%↑

UNH

384.16

+0.13%↑

AZN

188.09

+1.01%↑

LLY

1,061.41

+3.42%↑

JNJ

234.23

+2.48%↑

ABBV

217.56

+2.78%↑

UNH

384.16

+0.13%↑

AZN

188.09

+1.01%↑

LLY

1,061.41

+3.42%↑

JNJ

234.23

+2.48%↑

ABBV

217.56

+2.78%↑

UNH

384.16

+0.13%↑

AZN

188.09

+1.01%↑

Начало・Списък с акции・MacroGenics Inc

MacroGenics Inc

Отворен

СекторЗдравеопазване

4.37 0.46

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

4.22

Максимум

4.57

Ключови измерители
By Trading Economics
Приходи	-23M -37M
Продажби	-20M 21M
EPS	-0.58
Марж на печалбата	-177.011
Служители	293
EBITDA	-17M -32M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+41.93% upside

Дивиденти
By Dow Jones
Следващи печалби	12.08.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	89M 276M
Предишно отваряне	3.91
Предишно затваряне	4.37

Настроения в новините

By Acuity

29%

71%

66 / 345 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Neutral Evidence

1.47 / 1.64 Подкрепа & съпротива

MacroGenics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

21.05.2026 г., 22:48 ч. UTC

Придобивния, сливания и поглъщания

Conduent to Sell Public Transit Business to Modaxo for $164 Million

21.05.2026 г., 16:49 ч. UTC

Печалби

Walmart's Fuel Business Benefits from Rising U.S. Gas Prices, Though Volume Per Transaction Falls -- OPIS

21.05.2026 г., 16:26 ч. UTC

Значими двигатели на пазара

Spotify Technology Shares Up Amid New AI Tool For Remixing Songs

21.05.2026 г., 23:51 ч. UTC

Пазарно говорене

Nikkei Might Rise on Continued Hopes for Possible U.S.-Iran Deal -- Market Talk

21.05.2026 г., 23:37 ч. UTC

Печалби

Lenovo Group 4Q Oper Profit $886.0M Vs. $331.0M >0992.HK

21.05.2026 г., 23:37 ч. UTC

Печалби

Lenovo Group 4Q Rev $21.60B Vs. $16.98B >0992.HK

21.05.2026 г., 23:37 ч. UTC

Печалби

Lenovo Group 4Q Net $521.0M Vs. Net $90.0M >0992.HK

21.05.2026 г., 23:34 ч. UTC

Пазарно говорене

Gold Edges Lower Amid Mixed Sentiment -- Market Talk

21.05.2026 г., 23:30 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

21.05.2026 г., 23:30 ч. UTC

Пазарно говорене

Napier Port Loses Bull Despite Robust 1H Result -- Market Talk

21.05.2026 г., 22:33 ч. UTC

Придобивния, сливания и поглъщания

Conduent to Sell Public Transit Business to Modaxo for $164M

21.05.2026 г., 21:53 ч. UTC

Печалби

Marvell Stock Notches Its 15th Record Closing High This Year -- Barrons.com

21.05.2026 г., 21:02 ч. UTC

Печалби

These Stocks Are Today's Movers: Nvidia, IBM, Rigetti, Nebius, Bloom Energy, Applied Digital, Intuit, D-Wave, Spotify, and More -- Barrons.com

21.05.2026 г., 20:55 ч. UTC

Печалби

Walmart Sales Rise as It Navigates Higher Fuel Prices -- 2nd Update

21.05.2026 г., 20:30 ч. UTC

Горещи акции

Stocks to Watch Recap: Nvidia, Spotify, Stellantis, Intuit -- WSJ

21.05.2026 г., 20:20 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

21.05.2026 г., 20:20 ч. UTC

Пазарно говорене

Mexico's Revised 1Q GDP Seen Confirming Contraction -- Market Talk

21.05.2026 г., 20:20 ч. UTC

Печалби

Webull 1Q Adj EPS 3c >BULL

21.05.2026 г., 20:20 ч. UTC

Печалби

Webull 1Q Rev $159.9M >BULL

21.05.2026 г., 20:18 ч. UTC

Пазарно говорене

Mexico's Inflation Seen Easing in Early May -- Market Talk

21.05.2026 г., 20:18 ч. UTC

Печалби

Webull 1Q Loss/Shr 4c

21.05.2026 г., 19:43 ч. UTC

Пазарно говорене

Oil Futures Lose Ground on Hopes for U.S.-Iran Deal -- Market Talk

21.05.2026 г., 19:33 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures Edge Up in Steady Trading -- Market Talk

21.05.2026 г., 18:58 ч. UTC

Печалби

Nvidia Is Now the Megacap Cash Machine, and Big Tech Is Footing the Bill -- Barrons.com

21.05.2026 г., 18:15 ч. UTC

Пазарно говорене

Gold Higher For Second Consecutive Day -- Market Talk

21.05.2026 г., 17:40 ч. UTC

Пазарно говорене

Prolonged War Putting Energy Normalcy Further Away -- Market Talk

21.05.2026 г., 17:04 ч. UTC

Пазарно говорене

SpaceX Revealed as Top 10 Bitcoin Holder -- Market Talk

21.05.2026 г., 17:01 ч. UTC

Печалби

These Stocks Are Today's Movers: Nvidia, IBM, Rigetti, GlobalFoundries, Nebius, Applied Digital, Intuit, Spotify, and More -- Barrons.com

21.05.2026 г., 16:20 ч. UTC

Пазарно говорене

Печалби

Stellantis Targets Distant but Constructive -- Market Talk

21.05.2026 г., 16:20 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

Сравнение с други в отрасъла

Ценова промяна

MacroGenics Inc Прогноза

Ценова цел

By TipRanks

41.93% нагоре

12-месечна прогноза

Среден 6.33 USD 41.93%

Висок 9 USD

Нисък 4 USD

Според 5 анализатори от Wall Street, предложили 12-месечна ценова цел за MacroGenics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

5 ratings

Купи

Задържане

Продай

Според 5 анализатори, дали борсови рейтинги на MacroGenics Inc през последните 3 месеца.

Техническа оценка

By Trading Central

1.47 / 1.64Подкрепа & съпротива

The bullish and bearish events are balanced.

Recent bullish events outweigh bearish events.

All events are bearish.

Настроение

By Acuity

66 / 345 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно MacroGenics Inc

MacroGenics, Inc., a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. In addition, it develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, a humanized monoclonal antibody targeting programmed death receptor-1; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.